Research programme: anti-cancer protein therapeutics - Five Prime Therapeutics

Drug Profile

Research programme: anti-cancer protein therapeutics - Five Prime Therapeutics

Alternative Names: FPA 005; FPT 040; FPT 047

Latest Information Update: 26 Nov 2014

Price : $50

At a glance

  • Originator Five Prime Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunotherapies; Monoclonal antibodies; Proteins
  • Mechanism of Action Protein modulators; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer; Gastric cancer

Most Recent Events

  • 30 Sep 2014 Five Prime Therapeutics files an IND application with the US FDA for Cancer
  • 30 Sep 2014 US FDA approves IND application for FPA 144 for Cancer
  • 03 Jul 2014 Five Prime Therapeutics announces intention to submit IND to the US FDA in 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top